63O - A nation-wide multicenter 10-Year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Breast cancer
Topics Cytotoxic agents
Breast Cancer, Early Stage
Presenter Qiao Li
Citation Annals of Oncology (2016) 27 (suppl_9): ix19-ix29. 10.1093/annonc/mdw575
Authors Q. Li1, P. Zhang1, Z. Yang2, J. Fan2, J. He3, B. Zhang4, H. Yang5, X. Xie6, Z. Tang7, H. Li8, Y. Qiao2
  • 1Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), 100021 - Beijing/CN
  • 2Cancer Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), 100021 - Beijing/CN
  • 3Department Of Oncology Surgery, First Affiliated Hospital of Xi'an Jiaotong University (School of Medicine), 100021 - Xi'an/CN
  • 4Breast Surgery, Liaoning Cancer Hospital & Institute, 356666 - Shenyang/CN
  • 5Breast Surgery, Zhejiang Cancer Hospital, 333222 - Hangzhou/CN
  • 6Breast Surgery, Cancer Centre Sun Yat-Sen University, 300998 - Guangzhou/CN
  • 7Breast-thyroid Surgery, Central South University Xiangya No.2 Hospital, 100021 - Changsha/CN
  • 8Breast Surgery, Sichuan Provincial People's Hospital. Sichuan Medical Science Academy, 349887 - Chengdu/CN

Abstract

Background

We aimed to evaluate trends and factors associated with chemotherapeutic decisions in Chinese females with breast cancer.

Methods

We retrospectively analyzed demographic and pathological data along with chemotherapeutic information of 4211 breast cancer patients randomly selected from representative hospitals of 7 traditional areas in China between 1999 and 2008.

Results

A total of 3271 cases (77.7%) received adjuvant chemotherapy (ACT), 558 (13.3%) received neoadjuvant chemotherapy (NACT), and 392 (9.3%) received chemotherapy for metastatic disease. In adjuvant settings, age, stage, HR and HER2 status were independent factors affecting the use of ACT (P 

Conclusions

To our knowledge, this is the first nationwide multi-center study of chemotherapy in Chinese breast cancer patients. Major changes have taken place in chemotherapy for early and metastatic disease in China during this 10-year interval, which reflected the incorporation of key evidence and guidelines into Chinese medical practice.

Clinical trial indentification

Legal entity responsible for the study

Cancer Hospital, Chinese Academy of Medical Sciences (CAMS)

Funding

Pfizer

Disclosure

All authors have declared no conflicts of interest.